Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b